We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Urine Test Predicts Acute Kidney Injury Prognosis

By LabMedica International staff writers
Posted on 03 Mar 2015
The severity of the acute kidney injury (AKI) condition can range from minor loss of kidney function to complete kidney failure, and 50% to 60% of people who develop the condition die as a result and this figure has not changed in the last four decades. More...


In AKI the kidneys suddenly stop working properly and it often occurs as a result of something which gives the kidneys a “shock” such as an operation, an infection or severe illness, but it is not caused as a result of a physical blow to the body. AKI can become a life-threatening problem within hours, meaning that early recognition and prompt treatment are crucial.

Scientists at Cardiff University (UK) are investigating whether the urine of patients with AKI could give previously hidden clues to how their condition will progress, and show how likely they are to recover from their illness. The team will collect urine samples from patients with AKI and evaluate the ability of micro ribonucleic acid (RNA) levels to predict what subsequently happens to that individual. Different levels of microRNAs could indicate how likely a patient is to recover from the condition, or how likely it is that their condition will deteriorate. This newly discovered group of microRNA molecules could help predict the progression of AKI as previous data has shown that the levels of these molecules change in AKI, and the team will investigate this further.

Existing tests for AKI include monitoring a patient's urine output, and measuring the amount of toxins building up in their blood stream as a result of kidney failure. Both show that the kidneys are not working properly, but these measures can take hours to change and may not show a problem immediately. AKI affects one in six people who are admitted to hospital, causing around 40,000 deaths every year in the UK and an earlier report suggests that up to 30% of cases may be preventable. Timothy Bowen, PhD, and his team at Cardiff University have received funding of almost GBP 200,000 from Kidney Research UK (Peterborough, UK). They hope their work will lead to the development of new tests to show the status of AKI in patients, so doctors can monitor them accordingly.

Dr. Bowen, said, “Even though AKI is preventable, it has a very high mortality rate. We therefore wish to find ways to identify which AKI patients are most at risk of progressing to irreversible kidney failure. This will allow doctors to monitor these patients closely, and treat them sooner, to prevent this happening. We're hopeful that, in time, this work will help us to develop new methods to screen for AKI. Ideally, we'd like to produce a traffic light system enabling doctors to say 'this patient is at increased risk of kidney failure and will require closer monitoring.”

Related Links:

Cardiff University 
Kidney Research UK



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.